A NEW treatment for multiple sclerosis has been made available for thousands of Scottish sufferers for the first time.
Alemtuzumab, also known as Lemtrada, can be used to treat NHS patients after it was ruled to be good value for money, despite a £56,000 price tag.
An estimated 9,500 people in Scotland who have the more common relapsing remitting form of MS will become eligible to access the drug following the decision by the Scottish Medicines Consortium (SMC).
Scotland has the highest prevalence of MS in the world, with more than 11,000 people living with the condition.
Originally developed as a cancer treatment, alemtuzumab has been shown to reduce the frequency and severity of relapses, during which patients experience episodes of worsening neurological symptoms over a sustained period. The episodes can last weeks or months, may require hospital treatment and leave lingering health problems.
Trials have shown that the drug also slows down progression of physical disability and offers added convenience to patients, who receive five infusions on consecutive days before returning a year later for three more daily doses, rather than an ongoing regime of injections.
Dr Belinda Weller, a consultant neurologist at the Western General Hospital in Edinburgh, said that while patients would continue to be monitored closely, some would never need another alemtuzumab treatment following the first two courses.
"This is a highly effective drug," she said. "It's up there with the most effective treatments we've got. It might not be for everybody and it comes with potential side effects, but it's another option. Scotland has one of the highest MS prevalence rates in the world, so any new development is important.
"My feeling is that this will be used for those with a very active disease from the outset or who are put on one of the other treatments and still have high relapse patterns."
The drug, which has been developed in Cambridge, was shown to be more effective than interferon injections in trials. It was approved in England earlier this year.
The SMC said that while it was not fully understood how alemtuzumab worked, it rapidly reduced the numbers of two types of white blood cells involved in causing nerve damage in MS patients. MS causes the body's immune system to attack proteins that protect nerve fibres in the brain and spinal cord, disrupting the central nervous system.
Nick Rijke, executive director of policy and research at the MS Society, described the approval of alemtuzumab as a major step forward.
He added: "This drug has taken decades to develop, and while it's not without risk, it's proven to be a highly effective medicine for people with relapsing remitting MS. We look forward to seeing it made available to those who could benefit."
Meanwhile, other treatments approved by the SMC yesterday included injections of rituximab, which is used for non-Hodgkin's lymphoma. The drug had previously been licenced for intravenous use.
However, an application for blood cancer treatment pomalidomide was rejected as it not considered to offer value for money.
Dr Adrian Kilcoyne, medical director for manufacturer Celgene UK, said: "We are obviously disappointed with today's decision, especially since the SMC acknowledged that pomalidomide substantially improved the life expectancy of patients with relapsed and refractory multiple myeloma.
"We will of course do everything we can to try and ensure that patients in Scotland are able to access the treatment and have therefore already re-entered into discussions with the SMC."
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereComments are closed on this article